Zelira Therapeutics Ltd
ZLD
Company Profile
Business description
Zelira Therapeutics Ltd is a biotechnology company focused on developing a range of cannabinoid-based formulations for the treatment of various medical conditions in Australia. The company is involved in a human clinical trial program focused on insomnia, autism, and eczema; and a pre-clinical research program to examine the effect of cannabinoids in breast, brain, and pancreatic cancer.
Contact
101 St George’s Terrace
Level 3
PerthWA6000
AUST: +61 865580886
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2025
Employees
8
Stocks News & Analysis
stocks
ASX shares plunge but remain undervalued
Shares drop 17% after guidance is revised but we still see value.
stocks
Ask the analyst: Why have markets shunned APA Group?
Australia's premier gas infrastructure firm used to be a market darling, but its shares have taken a severe de-rating in recent years.
stocks
The 10 best US dividend stocks
These undervalued stocks with reliable dividends are worth considering.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,543.70 | 34.10 | -0.40% |
| CAC 40 | 7,431.04 | 59.24 | -0.79% |
| DAX 40 | 20,214.79 | 102.31 | -0.50% |
| Dow JONES (US) | 41,938.45 | 696.75 | -1.63% |
| FTSE 100 | 8,248.49 | 71.20 | -0.86% |
| HKSE | 19,064.29 | 176.60 | -0.92% |
| NASDAQ | 19,161.63 | 317.25 | -1.63% |
| Nikkei 225 | 39,190.40 | 414.69 | -1.05% |
| NZX 50 Index | 12,895.98 | 47.76 | -0.37% |
| S&P 500 | 5,827.04 | 91.21 | -1.54% |
| S&P/ASX 200 | 8,294.10 | 35.10 | -0.42% |
| SSE Composite Index | 3,168.52 | 42.87 | -1.33% |